NASH treatments

View All

Nonalcoholic Steatohepatitis (NASH) Therapeutics Market Outlook
Nonalcoholic Steatohepatitis Treatment Market: Which Pipeline Therapy Will Steal the Spotlight?

Non-alcoholic fatty liver disease is one of the most common causes of liver disease in the United States. As per the National Institute of Diabetes and Digestive and Kidney Diseases, only a small number of NAFLD patients possess NASH. It is estimated that about 24% of U.S. adults have NAFLD, among which around 20%-...

Find More

Another Failed NASH Drug; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; TLX66 in AL Amyloidosis
TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug

TLX66 Meets Study Objectives, Holding Out in AL Amyloidosis Telix Pharmaceuticals reported the results from the TRALA trial (Targeted Radiotherapy for AL Amyloidosis), a Phase I/IIa trial evaluating the safety and toxicity of TLX66 as the sole bone marrow conditioning agent prior to autologous hematopoietic stem...

Find More

NASH upcoming therapies
What lies in the future for NASH upcoming drugs?

NAFLD is one of the leading causes of liver damage in the younger population. The increasing NAFLD prevalence runs parallel with the increasing trends in obesity among people. However, this does not imply that the lean population does not get affected by it. Global NAFLD prevalence is estimated to be as high as One...

Find More

World Pharma News
EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline

EU approves the use of Libtayo for cutaneous squamous cell carcinoma The National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has issued guidelines regarding the funding of Libtayo (cemiplima). Libtayo, co-developed by Sanofi and Regeneron, was granted...

Find More

NASH Emerging therapies
NASH Emerging Therapies

Earlier in our article, we discussed how mostly off-label therapies so far dominate the NASH therapeutics market. So, let us dig deeper into it and find out what can we expect in the coming years in term of NASH treatments. As we know, there is no approved therapy available for NASH, and many Doctors rely on off-la...

Find More

NASH therapies
Off-label therapies dominate NASH Market Share

NASH market share of off label therapies, it will keep on experiencing a steady growth until a standard approved therapy enters the NASH treatment market. Non-alcoholic fatty liver disease (NAFLD), is the most common group of conditions in which there is an excess fat accumulation in the liver in people who i...

Find More